A New TRT Trial Improved Desire, Not Erections. That Difference Matters.

A 2026 randomized clinical trial found that testosterone replacement therapy increased sexual desire and sexual activity in a carefully selected group of prostate cancer survivors. It did not improve erectile function. That split is clinically important because libido and erections overlap, but they are not the same biological problem.

The study is also narrower than the headline may sound. It enrolled men with low-grade, organ-confined prostate cancer who had undergone radical prostatectomy, maintained an undetectable prostate-specific antigen for at least two years, and had confirmed low testosterone plus symptoms. Treatment lasted 12 weeks. No biochemical recurrence occurred during the study, but the trial was not large or long enough to establish long-term cancer safety.

The useful conclusion is not that testosterone is a cure for sexual dysfunction after prostate cancer, or that TRT is now proven safe for every survivor. It is that, in one tightly defined population, restoring testosterone improved desire and activity without repairing erectile function.

What the 2026 Trial Actually Tested

The randomized, placebo-controlled phase 2 trial in prostate cancer survivors enrolled 136 men at two academic medical centers. Participants were at least 40 years old and had previously undergone radical prostatectomy for organ-confined, low-grade prostate cancer with a Gleason score of 6, or 7 with a 3 + 4 pattern.

Eligibility was unusually specific:

• PSA had to remain undetectable for at least two years after surgery.
• The mean of two testosterone measurements had to be below 275 ng/dL.
• Men also had to report low libido, erectile dysfunction, or fatigue.
• Men with high-grade disease were not represented.
• Men treated with radiation therapy or androgen deprivation therapy were not represented.

Participants received either testosterone cypionate 100 mg by intramuscular injection once weekly or placebo for 12 weeks. The primary efficacy outcome was sexual activity. Secondary outcomes included sexual desire, erectile function, mood, body composition, aerobic capacity, and physical function.

This was a proof-of-concept trial, not a broad clearance for TRT after prostate cancer.

The Main Finding: Desire and Activity Improved

Compared with placebo, testosterone increased sexual activity by an adjusted 0.91 daily events, with a 95% confidence interval from 0.56 to 1.26. Sexual desire and the sexual domain of a prostate cancer quality-of-life measure also improved.

Those results are plausible. Testosterone is involved in central sexual motivation, interest, and responsiveness. In men with confirmed testosterone deficiency, restoring testosterone can improve the drive to initiate or engage in sexual activity.

The trial also reported improvements in negative affect, body composition, loaded stair-climbing power, and peak aerobic performance. Those were secondary outcomes from a short study, so they should not be converted into promises about how an individual patient will feel or perform.

Erectile Function Did Not Improve

The finding most likely to be lost in social-media summaries is straightforward: erectile function did not change.

That does not make the trial negative. It makes the result more precise. Desire is the interest in sexual activity. An erection is a vascular and neurologic event that depends on blood flow, intact nerves, smooth-muscle relaxation, medication effects, metabolic health, and psychological context.

Radical prostatectomy can affect the nerves and blood vessels involved in erections. Testosterone cannot be assumed to reverse surgical nerve injury or restore vascular function. A man may want sex more often while still having difficulty achieving or maintaining an erection.

AlphaMD's guide to why erectile dysfunction is not always a testosterone problem explains why low desire and impaired erections require different diagnostic questions.

Libido and Erections Should Be Measured Separately

The trial reinforces a practical rule: “sexual function” is too broad to be a useful treatment target by itself.

A clinical discussion should separate at least four outcomes:

• Sexual desire: Do you think about or want sexual activity?
• Arousal: Do you feel mentally and physically activated by sexual cues?
• Erectile function: Can you develop and maintain sufficient rigidity?
• Sexual activity and satisfaction: Are you having the type and frequency of sexual activity you want?

Those outcomes can move in different directions. TRT may improve desire in a man whose testosterone is genuinely low while his erection problem remains because of diabetes, vascular disease, medication effects, sleep apnea, anxiety, pelvic surgery, or another cause.

The opposite can also occur. A medication that improves penile blood flow may improve erections without increasing desire.

This is why a better treatment question is not “Did TRT fix my sex life?” It is “Which specific part changed, and which part did not?”

What the Trial Does Not Prove About Prostate Cancer Safety

No participant met the study definition of biochemical recurrence, a PSA level of at least 0.2 ng/mL, during treatment or the three-month follow-up. That is reassuring within the observed period. It is not proof of long-term oncologic safety.

The authors explicitly stated that the trial was neither long enough nor large enough to evaluate clinical recurrence or long-term safety. Prostate cancer recurrence can take years to become detectable. A 12-week exposure period and short follow-up cannot answer whether TRT changes that risk over a much longer horizon.

The American Urological Association testosterone-deficiency guideline advises that men with testosterone deficiency and a history of prostate cancer be told that evidence is inadequate to quantify the risk-benefit ratio of testosterone therapy. The guideline was validity-confirmed in 2024, and individual decisions still require coordination with the clinicians responsible for a man's cancer surveillance and hormone care.

AlphaMD's broader review of TRT and prostate cancer provides context for the observational evidence, PSA monitoring, and ongoing uncertainty. This new randomized trial strengthens the short-term evidence for a narrow post-prostatectomy group, but it does not erase the need for individualized risk assessment.

Who the Findings Apply To, and Who They Do Not

The study population matters as much as the result.

The findings are most relevant to men who resemble the participants: men with symptomatic testosterone deficiency, prior radical prostatectomy for low-grade organ-confined disease, and an undetectable PSA for at least two years.

The findings should not be generalized to:

• Men with untreated or active prostate cancer
• Men with metastatic disease
• Men with high-grade or higher-risk pathology
• Men receiving or previously treated with androgen deprivation therapy
• Men treated with radiation rather than radical prostatectomy
• Men whose PSA is detectable or rising
• Men seeking testosterone without confirmed biochemical deficiency and compatible symptoms

The trial also does not establish the best dose, formulation, target testosterone level, or surveillance plan for all prostate cancer survivors.

A Better Way to Evaluate Sexual Symptoms on TRT

If desire improves but erections do not, simply increasing the testosterone dose may miss the problem and increase treatment risk.

A licensed clinician may consider:

• Whether testosterone deficiency was correctly diagnosed with compatible symptoms and appropriately timed laboratory testing
• Whether testosterone levels and treatment exposure are in the intended range
• Whether erectile dysfunction began before or after prostate surgery
• Blood pressure, diabetes, smoking, lipids, and other vascular risk factors
• Medication effects, including some antidepressants and antihypertensives
• Sleep quality, alcohol use, stress, depression, and relationship factors
• Whether a phosphodiesterase-5 inhibitor or another evidence-based ED treatment is appropriate
• Whether urology, sexual-medicine, or oncology input is needed

An erection problem can be a cardiovascular signal. AlphaMD's article on erectile dysfunction as a blood-vessel problem explains why persistent ED deserves more than a hormone adjustment.

Frequently Asked Questions

Did TRT improve erections in the 2026 prostate cancer survivor trial?

No. TRT improved sexual desire and sexual activity compared with placebo, but erectile function did not change.

Does this trial prove TRT is safe after prostate cancer?

No. No biochemical recurrence occurred during the short trial and follow-up, but the study was not large or long enough to determine clinical recurrence or long-term cancer safety.

Can a man have higher libido and still have erectile dysfunction?

Yes. Desire and erectile function involve overlapping but different systems. A man can feel more interested in sex while a vascular, neurologic, medication-related, or postsurgical erection problem remains.

Should men with a history of prostate cancer start TRT?

This trial does not support a universal recommendation. Decisions should be individualized and coordinated with appropriately licensed clinicians who can review cancer characteristics, PSA history, symptoms, laboratory confirmation of testosterone deficiency, alternatives, and surveillance.

Should TRT be increased if erections do not improve?

Not automatically. Failure of erections to improve may indicate that the primary cause is not testosterone deficiency. Dose changes should be based on clinical evaluation, treatment response, laboratory results, and safety monitoring rather than erectile symptoms alone.

The Bottom Line

The 2026 trial offers a cleaner answer than the usual “TRT improves sexual function” headline. In carefully selected men after radical prostatectomy for low-grade prostate cancer, testosterone improved desire and sexual activity. It did not improve erectile function.

That distinction can prevent two common mistakes: promising that testosterone will fix every sexual symptom, and treating a short trial without recurrence as proof of long-term cancer safety. The next step is larger, longer research and careful patient selection, not a blanket conclusion.

This article is for educational purposes and is not medical advice. Medical decisions after prostate cancer should be made with appropriately licensed clinicians, including the clinicians responsible for cancer surveillance.